| DB ID | MyCo_2412 |
| Title | Antibodies against glucan, chitin, and Saccharomyces cerevisiae mannan as new biomarkers of Candida albicans infection that complement tests based on C. albicans mannan |
| Year | 2008 |
| PMID | 18971303 |
| Fungal Diseases involved | Candida albicans infection |
| Disease | Candidiasis (Candida Infection) |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | albicans |
| Organism | Candida albicans |
| Ethical Statement | Written, informed consent was obtained from all patients before serum sam-ples were taken from the patients, and the study was approved by the institu-tional review board of Lille University Hospital. |
| Site of Infection | Unspecified |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | ALCA |
| Biomarker Full Name | antibodies against synthetic disaccharide fragments of glucans (laminaribioside) |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | France |
| Cohort | Sixty-nine serum samples were selected retrospectively between January 2005 and December 2006 from 18 patients hospitalized in Lille University Hospital and Saint Antoine University Hospital, Paris, France, who developed ICIs. |
| Cohort No. | 18 |
| Age Group | 48±19 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Sub Technique | ELISA |
| Technique | Immunoassay |
| Analysis Method | ELISA Based |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | FDA Approved -Platelia Aspergillus Ag ELISA |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
